Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | +3.47% | +7.19% | -45.51% |
11/04 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
11/04 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
Sales 2024 * | 28.05M 2.34B | Sales 2025 * | 72.09M 6.01B | Capitalization | 42M 3.5B |
---|---|---|---|---|---|
Net income 2024 * | -1M -83.42M | Net income 2025 * | 39M 3.25B | EV / Sales 2024 * | 1.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.58 x |
P/E ratio 2024 * |
246
x | P/E ratio 2025 * |
0.92
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.89% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | +3.47% | ||
1 week | +7.19% | ||
Current month | +3.47% | ||
1 month | -26.46% | ||
3 months | -39.93% | ||
6 months | -42.86% | ||
Current year | -45.51% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | 01/11 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | 14/02 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 01/20/01 |
James Manuso
BRD | Director/Board Member | 75 | 01/19/01 |
Susan Benton
BRD | Director/Board Member | 59 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
01/24/01 | 1.64 | +3.47% | 45,231 |
30/24/30 | 1.585 | -3.94% | 37,052 |
29/24/29 | 1.65 | +2.48% | 82,473 |
26/24/26 | 1.61 | +4.89% | 113,959 |
25/24/25 | 1.535 | +0.33% | 110,754 |
Delayed Quote Nasdaq, May 02, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.51% | 42M | |
+33.25% | 699B | |
+25.80% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.51% | 236B | |
+5.18% | 198B | |
-9.86% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- OCUP Stock